Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer

Ipsen has become the newest entrant in the antibody-drug conjugate (ADC) race, handing over around $90 million in near-term payments to Sutro Biopharma in return for the global rights to a preclinical candidate.